Background
• Individuals with Type 1 diabetes mellitus (T1DM) or Type 2 diabetes mellitus (T2DM) may be at risk for a range of complications including retinopathy, nephropathy, limb amputation, and the development of cardiovascular complications.
• Centers for Medicare and Medicaid Services (CMS) rates Medicare Part C and D plans on several quality measures for the purpose of educating consumers on the quality of Medicare plans in the marketplace including increasing the transparency of health plan performance and comparison. 1 • Specific quality measures for Medicare Part C and D focus on indicators that track quality of medical care and medication management, in diabetic patients. 1 ,2 • It remains unclear if attaining these CMS diabetes quality indicators improves outcomes.
Objective
Assess the achievement of eight diabetes-related quality measures, at the patient level, and examine whether achievement was associated with fewer complications.
Methods
• Study Design: Retrospective cohort study • Data Source: Humana administrative database, which contains integrated medical, pharmacy, and lab-related claims, and member-level achievement indicators for Medicare Part C quality measures. Medicare Part D measures were provided to Humana by Accumen, LLC, a third party vendor.
• Patient Selection:
-Medicare Advantage plan with Prescription Drug coverage (MAPD) patients, aged 18 to 75 years as of December 31, 2011, continuously enrolled from January 1, 2010 to December 31, 2011, with a diagnosis of diabetes during the pre-index period, defined by at least one of the following:  ≥1 prescription claims for insulin or oral hypoglycemics/antihyperglycemics.  ≥2 two face-to-face encounters, in an outpatient setting or nonacute inpatient setting, on different dates of service, with a diagnosis of diabetes (250.x).  ≥1 face-to-face encounter in an acute inpatient or ED setting, with a diagnosis of diabetes.
-Exclusions included:
 Diagnosis of gestational diabetes (648.8) or pregnancy (630.xx-679.xx or v22.x-v24.x) at any position during the study period.  Diagnosis of both T1DM (250.x1 or 250.x3) and T2DM (all other 250.x ICD-9 CM codes) AND the presence of ≥1 prescription claims for oral hypoglycemics/antihyperglycemics.  Long-term care facility stay >30 days at any point during the study period.
-Quality Measure-Specific Exclusion Criteria:
 Each quality measure has its own CMS-defined exclusion criteria 1 and sample size.
• Baseline Characteristics: Pre-index demographic and clinical characteristics were assessed.
• Quality Measures: Eight DM-related quality measures 1 
Limitations
• This study utilized data from Humana MAPD health plans only and may not be generalizable.
• Due to limitations of data provided by Humana's quality data third party vendor, a number of plans were excluded due to incomplete data.
• Causal inference cannot be directly determined as relationships between quality measure achievement and outcomes were based on statistical associations and temporal relationships.
Results Summary
• Cohort size ranged from 4,464 to 159,454, depending on the quality measure and patient-level data availability (Table 1 ).
• Most patients (>80%) achieved LDL-C screening, nephropathy, and adherence standards (Figure 1 ).
• <1% of patients exceeded dosing standards for biguanides, sulfonylureas, and TZDs ( Figure 1 ).
• Eye screening and use of appropriate anti-hypertensive treatments had low achievement levels (50.3% and 54.2%, respectively; Figure 1 ).
• A majority (61%) of patients achieved HbA1c<9% while 29% achieved LDL-C control <100mg/dl ( Figure 1 ).
• Statistically significant univariate associations were identified for new or worsening diabetes complications and achievement of: HbA1c Poor Control >9%, LDL-C Screening, Adherence, DMD-Biguanides, Diabetes Treatment (Table 2 ).
• Logistic regression estimates showed that the odds of developing new or worsening diabetes complications ( 
Conclusion
The assessment of a 1-year measurement period suggests that attainment of several CMS diabetes quality measures may be associated with lower new or worsening complication risk. Follow-up longitudinal studies may provide clarity on the long-term impact of achieving quality measures.
